Indeno[1,2-c]isoquinolines as enhancing agents on all-trans retinoic acid-mediated differentiation of human myeloid leukemia cells
- Authors
- Kim, Seung Hyun; Oh, Sang Mi; Song, Ju Han; Cho, Daeho; Le, Quynh Manh; Lee, Suh-Hee; Chob, Won-Jea; Kim, Tae Sung
- Issue Date
- 1-2월-2008
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- All-trans retinoic acid; Differentiation; Indenoisoquinoline; Leukemia
- Citation
- BIOORGANIC & MEDICINAL CHEMISTRY, v.16, no.3, pp.1125 - 1132
- Indexed
- SCIE
SCOPUS
- Journal Title
- BIOORGANIC & MEDICINAL CHEMISTRY
- Volume
- 16
- Number
- 3
- Start Page
- 1125
- End Page
- 1132
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/124104
- DOI
- 10.1016/j.bmc.2007.10.086
- ISSN
- 0968-0896
- Abstract
- Induction of differentiation is a new and promising approach to cancer therapy, well illustrated by the treatment of acute myeloid leukemia with all-trans retinoic acid (ATRA). Using combination of ATRA and chemotherapy, adverse effects such as retinoic acid syndrome have decreased, and long-term survival has improved. In this study, we demonstrated that the indeno[1,2-c]isoquinolines markedly enhanced differentiation of human myeloid leukemia HL-60 and NB4 cells when simultaneously combined with a low dose of ATRA. Of the tested compounds, 6-(4-methoxybenzyl)-2,11-dimethyl-6H, 11H-indeno[1,2-c]isoquinolin-5-one (IIQ-16), an indeno[1,2-c]isoquinoline derivative, showed the highest differentiation-enhancing activity via a pathway involved with protein kinase C, extracellular signal-regulated kinase, and e-Jun N-terminal kinase. The ability to enhance the differentiation potential of ATRA by IIQ-16 may improve outcomes in the therapy of acute promyelocytic leukemia. (c) 2007 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Life Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.